Skip to content

Author

N. Azad

We have 3 of 76 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

BACKGROUND RAS mutations, as a group, are the most common oncogenic drivers of non-small-cell lung cancer (NSCLC), and they occur in approximately 30% of patients. Whether daraxonrasib (RMC-6236) - an oral RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate-bound mutant and wild-type RAS protein iso...

K. Arbour, S. Punekar, Jia Luo et al. · 1 citation
Sep 2026

Abstract PR010: A mutant KRAS-targeted peptide vaccine in combination with RAS(ON) multi-selective inhibition and immune checkpoint modulators enhances anti-tumor immunity in preclinical PDAC models

Recent clinical advances using RAS-targeted small-molecule inhibitors, including daraxonrasib, a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor, has shown promising responses but are limited in durability for pancreatic ductal adenocarcinoma (PDAC). Preclinical studies indicate that RAS inhibition ca...

Zi-Rui Zhu, Benjamin C. Barrett, Aadi Bhattacharya et al. · 0 citations
Aug 2026

Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.

Despite shared genomic drivers with PDAC, ASQ exhibits transcriptionally distinct features with spatially organized tumor and immune heterogeneity, supporting the need for subtype-specific therapeutic strategies.

S. Haldar, Meredith Wetzel, Jia-Yun Lu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.